Literature DB >> 11877301

High-affinity binding sites for heparin generated on leukocytes during apoptosis arise from nuclear structures segregated during cell death.

Milena A Gebska1, Ian Titley, Hugh F Paterson, Ricardo M Morilla, Derek C Davies, Alicja M Gruszka-Westwood, Vijay V Kakkar, Suzanne Eccles, Michael F Scully.   

Abstract

During cell death of human cultured leukocytes (Jurkat, HL-60, THP-1, U937) and freshly prepared leukocytes, we observed a greater than 100-fold increase in the affinity of apoptotic and necrotic cells for fluorescein isothiocyanate (FITC)-heparin in comparison with live cells. Binding of FITC-heparin was reversed in the presence of high ionic strength, unlabeled heparan sulfate, and heparin and pentosan polysulfate, but not in the presence of chondroitin and dermatan sulfates. During the course of cell death, the increase in the percentage of cells positive for annexin V binding correlated with the increase in the population positive for binding FITC-heparin. Confocal microscopy demonstrated that heparin binding to dead cells was restricted to 1 or 2 small domains on the surfaces of apoptotic cells and to larger, but still discrete, areas that did not localize with chromatin on ruptured necrotic cells. The heparin-binding domains originated from the nucleus and may correspond to the ribonucleoprotein-containing structures that have recently been shown to segregate within the nucleus of cells and to move onto the cell membrane. We observed that phagocytosis of dead Jurkat cells by monocyte-derived macrophages was blocked when the heparin-binding capacity of the dead cells was saturated by the addition of pentosan polysulfate. From this we concluded that the ability of dead cells to bind to heparan sulfate proteoglycans on the surfaces of macrophages may assist in phagocytic clearance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11877301     DOI: 10.1182/blood.v99.6.2221

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  DADLE induces a reversible hibernation-like state in HeLa cells.

Authors:  Lorella Vecchio; Cristiana Soldani; Maria Grazia Bottone; Manuela Malatesta; Terence E Martin; Lawrence I Rothblum; Carlo Pellicciari; Marco Biggiogera
Journal:  Histochem Cell Biol       Date:  2005-10-18       Impact factor: 4.304

Review 2.  Bemiparin: pharmacological profile.

Authors:  Carlos F Sánchez-Ferrer
Journal:  Drugs       Date:  2010-12-14       Impact factor: 9.546

3.  Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells.

Authors:  Takaharu Ichimura; Edwin J P V Asseldonk; Benjamin D Humphreys; Lakshman Gunaratnam; Jeremy S Duffield; Joseph V Bonventre
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

Review 4.  Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis.

Authors:  Therese M Chapman; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 5.  Clinical review: anticoagulation for continuous renal replacement therapy--heparin or citrate?

Authors:  Heleen M Oudemans-van Straaten; John A Kellum; Rinaldo Bellomo
Journal:  Crit Care       Date:  2011-01-24       Impact factor: 9.097

6.  C-reactive protein does not opsonize early apoptotic human neutrophils, but binds only membrane-permeable late apoptotic cells and has no effect on their phagocytosis by macrophages.

Authors:  Simon P Hart; Karen M Alexander; Shonna M MacCall; Ian Dransfield
Journal:  J Inflamm (Lond)       Date:  2005-05-31       Impact factor: 4.981

7.  HS and Inflammation: A Potential Playground for the Sulfs?

Authors:  Rana El Masri; Yoann Crétinon; Evelyne Gout; Romain R Vivès
Journal:  Front Immunol       Date:  2020-04-03       Impact factor: 7.561

8.  Hemostasis during low molecular weight heparin anticoagulation for continuous venovenous hemofiltration: a randomized cross-over trial comparing two hemofiltration rates.

Authors:  Heleen M Oudemans-van Straaten; Muriel van Schilfgaarde; Pascal J Molenaar; Jos Pj Wester; Anja Leyte
Journal:  Crit Care       Date:  2009-12-03       Impact factor: 9.097

9.  Bench-to-bedside review: Citrate for continuous renal replacement therapy, from science to practice.

Authors:  Heleen M Oudemans-van Straaten; Marlies Ostermann
Journal:  Crit Care       Date:  2012-12-07       Impact factor: 9.097

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.